ClinicalTrials.gg
RecruitingNCT06360380REFORM-HFUpdated Nov 2, 2026

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

An interventional study of AquaPass System in Chronic Heart Failure and CKD Stage 3, sponsored by AquaPass Medical Ltd.. Recruiting at 10 sites in 2 countries. Open to participants aged 21 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by AquaPass Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 2, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
21 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
974th of 1,602
40 · median 66
Started
2024
with 108 others
No phase
887 of 2,159
159 open now
Primary completion
2026-07
later than 92 of 438 live
Registered
1,908th of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 974th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 109 that started in 2024, is one of 887 with no phase, reaches primary completion later than 92 of the 438 other live ones, and was the 1,908th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 21 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The REFORM-HF study aims to test a new technology, AQUAPASS, designed to assist patients experiencing symptoms of fluid overload due to Heart Failure.

Patients will wear a lightweight suit that helps remove excess fluids through their sweat.

The investigators want to see if the AQUAPASS system can remove an additional 500mL of fluids during treatment, alongside patients' regular medications like diuretics.

Participants will be treated in the hospital or in the outpatient clinic.

Read the detailed description

This study is being conducted to demonstrate the safety and effectiveness of the AquaPass System in reducing fluid overload in patients with decompensated heart failure and chronic kidney disease stage 2-3 who are not responding adequately or resistant to current medical treatment.

The study checks if patients' fluid loss as a result of taking diuretics medications is improved when using AQUAPASS in parallel to this treatment.

The evaluation of success is done by comparing participants' weight before and after the use of the AQUAPASS system, to evaluate if the system effectively removes excess fluids.

Patients will also have blood and urine tests every morning to check how well their kidneys and heart are functioning.

The first visit will be observation only, without using AQUAPASS. This will serve as the baseline data. The investigators will compare the data of the AQUAPASS treatments with this baseline to measure the effectiveness of the system in removing excess fluids.

03

Conditions studied

  • Chronic Heart Failure
  • CKD Stage 3

Browse trials for

Keywords

  • Aquapass
  • Sweat Enhancement
  • Fluid removal
  • CHF
04

Who can participate

Ages eligible
21 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥21 years and \< 80 years
  2. Subject, with known decompensated heart failure Class II, III (as evaluated by an independent observer who is not on the study team) presenting with fluid overload, defined by a congestion score of ≥3, who are not responding adequately or are resistant to current medical treatment as evidenced by persistent or worsening congestion, despite a daily dose of 80 mg furosemide or greater or the equivalent dose of another loop diuretic .
  3. No change in diuretic dosage in the past 5 days
  4. Subjects with between 15-89 mL/min/1.73m2
  5. Baseline NT-proBNP ≥600 pg/mL
  6. Baseline systolic blood pressure ≥100 mmHg
  7. Subject is able and willing to provide written , inclusive of the release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation
  8. Subject is not participating in any clinical investigation that may interfere with the data collection or the results of this study

Exclusion criteria

Exclusion Criteria:

  1. Subject considered to be in the acute worsening of heart failure: Requiring invasive or non-invasive mechanical ventilation, mechanical circulatory support or is clinically unstable requiring pressors, inotropes, deterioration triggered by arrhythmia, infection, or other medical condition unrelated to fluid overload .
  2. Subject has any known or visible lower body (non-facial) skin condition (open wounds, ulcers, infections) that can potentially prevent using the wearable for the duration of the procedure
  3. Known allergy to Polyester or Thermoplastic polyurethane (TPU)
  4. Subject with severe peripheral arterial disease
  5. Subject is pregnant or planning to become pregnant within the study period, or a lactating woman.
  6. Subject with known hypothalamic disorders
  7. Subject with known hypohidrosis disorders
  8. Subjects with external medical technology dependency (gastric (G) tubes, ventilators, peripherally inserted central venous catheters, etc.)
  9. Subject with cystic fibrosis
  10. Subject with active infections
  11. Inability or unwillingness to comply with the study requirements
  12. Subjects with unstable electrolytes or acid-base balance (as per investigator's discretion)
  13. Known Severe aortic valve or mitral valve stenosis
  14. History of a heart transplant or actively listed for a heart transplant
  15. Implanted left ventricular assist device (LVAD) or implant anticipated in \<3 months
  16. Subject with a of less than 6 months, per investigator's discretion, due to malignant or non-cardiac comorbidities
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    AquaPass

    An AquaPass treatment session (up to 5-Hrs.) will be administered and supervised by certified study staff

    Device: AquaPass System

  • No intervention
    Control

    An observation visit, during which data will be collected on fluid intake, fluid output, congestion score, and body weight. These data will serve as a control for the efficacy primary endpoint comparison.

Interventions

  • DeviceAquaPass System

    a treatment session of up to 5 hours with the AquaPass system, evaluating net fluid removal for efficacy analysis and effect on vital signs for safety analysis

06

What researchers measure

Primary outcomes

  1. AQUAPASS Performance Evaluation

    Average Net Fluid Loss calculated as the difference in weight between pre- and post-AQUAPASS treatment sessions, in comparison to the Control Day observation. Total Average Net Fluid Loss during the Treatment Phase should be ≥ 500gr. as compared to the Total Average Net Fluid Loss during the Control Phase.

    Time frame: 5 days

Secondary outcomes

  1. AQUAPASS Safety Evaluation

    Incidence of device- and procedure-related side effects - defined as ANY of the following events during or immediately after device use: * loss of consciousness * acute confusion/disorientation * cardiac arrest * respiratory failure or seizure * decrease in systolic blood pressure ≥ 20 mmHg OR mean BP ≥ 10 mmHg WITH associated symptoms (cramping, headache, lightheadedness, vomiting, or chest pain) AND need for intervention (administration of fluids) * skin infections * skin burns

    Time frame: 6 hours

07

Study locations

10 of 10 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jul 2026, 23 months.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 23 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jul 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 11, 2024
StartActual
Aug 12, 2024
Primary completionActual
Jul 23, 2026was Aug 2026
CompletionEst.
Apr 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Jul 23, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Aug 2026→Jul 23, 2026 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06360380
Lead sponsor
AquaPass Medical Ltd.
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Aug 12, 2024
Primary completion
Jul 23, 2026
Completion
Apr 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Scott C Feitell, DO
Contact
scott.feitell@rochesterregional.org
(585) 442 5320
Julie Mooney, RN
Contact
julie.mooney@rochesterregional.org
585-738-3409
Scott C Feitell, DO
principal investigator · Rochester Regional Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion